- Medicine Name: Posluma
- API: Flotufolastat F 18
- Dosage Form & Strength: 296 MBq/mL to 5,846 MBq/mL (8 mCi/mL to 158 mCi/mL),multiple-dose vial
- Manufactured By: Blue Earth Diagnostics Ltd
Posluma is a groundbreaking radioactive diagnostic agent developed for precise and critical positron emission tomography (PET) imaging. It is specifically indicated for detecting prostate-specific membrane antigen (PSMA) positive lesions in men diagnosed with prostate cancer. Posluma plays a pivotal role in two key clinical scenarios:
Candidates for Initial Definitive Therapy: Posluma is a valuable tool for men with suspected metastatic prostate cancer who are in consideration for initial definitive therapy. Its diagnostic power aids in the accurate assessment of the extent of the disease, guiding clinicians in making informed decisions about the most appropriate treatment options.
Suspected Recurrence: For men with elevated serum prostate-specific antigen (PSA) levels, Posluma offers a reliable method for detecting suspected cancer recurrence. By providing precise imaging results, it assists healthcare professionals in identifying and addressing recurrent disease, ultimately influencing patient care and management.
Dosage and Administration
Recommended Radioactivity: The recommended Posluma dosage is 296 MBq (8 mCi), administered as an intravenous bolus injection. This carefully calibrated radioactivity dosage ensures accurate PET imaging results.
Optimal Imaging Timing: Initiate imaging approximately 60 minutes after Posluma administration. The scanning protocol should begin from the mid-thigh region and proceed to the base of the skull. This comprehensive approach enables a thorough assessment of PSMA-positive lesions.
Comprehensive Guidance: For detailed information on the preparation, handling, administration, imaging procedures, and radiation dosimetry, please refer to the complete prescribing information. This comprehensive resource ensures that healthcare professionals can utilize Posluma to its full potential, guaranteeing the highest standard of care for patients.
All Trademarks and Brands that appear on the website belong to their respective owners and indianpharmanetwork does not lay any claim on them we only provide Information.